Rheumatology Network's Top 5: September 3, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 3, 2022.

Patients with PsA More Likely to Experience Side Effects of Methotrexate

"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”

Autoimmune Disease Increases Risk of Developing Cardiovascular Disease

Although investigations have been performed on the association between inflammatory conditions and cardiovascular events, the effect of different conditions on cardiovascular diseases has not been analyzed on a large scale.

Tapering Biologics After Prolonged Inactive Disease may Benefit Pediatric Patients

Although effective therapies are crucial, adverse events, financial burden, and other factors make a "taper-to-target" approach appealing to both pediatric patients and their caregivers.

No Increased Risk of Insulin Resistance in Prednisone-Exposed Fetuses

Long-term corticosteroids during pregnancy is associated with maternal and fetal adverse outcomes which may influence the insulin resistance later in life.

2-Year Post-Biopsy Renal Response Predicts Long-Term Renal Survival in Lupus Nephritis

Previous renal response endpoints used in lupus nephritis trials lacked uniformity and their accuracy of long-term kidney survival prediction was questionable.